-
Electronic (PDF)
-
Site License
-
Enterprisewide
Post-Myocardial Infarction - Pipeline Review, H2 2011
Global Markets Direct, November 2011, Pages: 29
Post-Myocardial Infarction - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'Post-Myocardial Infarction - Pipeline Review, H2 2011', provides an overview of the Post-Myocardial Infarction therapeutic pipeline. This report provides information on the therapeutic development for Post-Myocardial Infarction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Myocardial Infarction. 'Post-Myocardial Infarction - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Post-Myocardial Infarction.
- A review of the Post-Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Post-Myocardial Infarction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Post-Myocardial Infarction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Post-Myocardial Infarction pipeline depth and focus of Post-Myocardial Infarction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Post-Myocardial Infarction Therapeutic Products under Development, Key Players in Post-Myocardial Infarction Therapeutics, Post-Myocardial Infarction Pipeline Overview, Post-Myocardial Infarction Pipeline, Post-Myocardial Infarction Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Myocardial Infarction Overview
Therapeutics Development
An Overview of Pipeline Products for Post-Myocardial Infarction
Post-Myocardial Infarction Therapeutics under Development by Companies
Post-Myocardial Infarction Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Post-Myocardial Infarction Therapeutics - Products under Development by Companies
Post-Myocardial Infarction Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Post-Myocardial Infarction Therapeutics Development
miRagen Therapeutics, Inc.
Post-Myocardial Infarction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Natrecor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN-1374 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post-Myocardial Infarction Therapeutics – Drug Profile Updates
Post-Myocardial Infarction Therapeutics - Discontinued Products
Post-Myocardial Infarction - Featured News
Sep 28, 2010: Trophos Initiates Clinical Development Of TRO40303
Mar 02, 2009: RegeneRx Completes Enrollment And Dosing Of Phase I Safety Trial For Potential Heart Drug
Sep 22, 2008: RegeneRx Enrolls First Subject In RGN-352 Phase IB Clinical Trial
Sep 08, 2008: RegeneRx Successfully Completes Phase IA Clinical Trial
Jul 03, 2008: RegeneRx Completes Enrollment And Dosing Of Phase IA Safety Trial For Potential Heart Drug
Nov 29, 2006: Resverlogix Corp Announced that Its Lead Compound RVX-208 Increases ApoA-I By 150% In First 24 Hours
Jun 01, 2002: Preparation For Phase III Clinicals: ProMetic And Menarini Biotech Achieve Milestone For Amediplase Manufacture
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Post-Myocardial Infarction, H2 2011
Products under Development for Post-Myocardial Infarction – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
miRagen Therapeutics, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Post-Myocardial Infarction Therapeutics – Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Post-Myocardial Infarction, H2 2011
Products under Development for Post-Myocardial Infarction – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Mid Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
